Cramer's 'Mad Money' Recap: The Fed's Reckless Moves

Cramer said he's been waiting for a pullback to recommend the stock. It's come down, he said, because they can't make enough product to meet demand. That's a high quality problem to have and leaves SIGM with pricing power.

Medicis' Anti-Wrinkle Treatment

Medicis Pharmaceutical's (MRX Quote) Jonah Shacknai joined Cramer on his show, where Cramer asked the CEO about his company's new anti-wrinkle treatment it just submitted for approval to the Food & Drug Administration.

"How is it different from Botox," Cramer asked.

The drug, Shacknai said, was the first neurotoxin approved anywhere in the world. Medicis licensed it from its French inventor and has been working really hard to bring it to market in the U.S., he said.

After many trials and tests, the data for the drug has come together regarding the safety and effectiveness of it, and Shacknai said he hopes it is approved.

He said Allergan (AGN Quote), the maker of Botox, is a very good company and respects its management. However, he believes Medicis is more connected to its customers than Allergan is.

Concerning the company's Restylane drug, Shacknai said Medicis is dominating that category as well, despite Allergen's rival Juvederm drug. Shacknai said he expects Restylane's business to go up.